GICS Sector : Healthcare
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements.Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum.
Haleon reported a 3.4% organic revenue growth in Q3 2025, driven by strong in-market execution and innovation pipeline, with price contributing 1.8% and volume mix 1.6%. The company's Oral Health segment was a standout performer, with 6.9% growth driven by innovation-led premiumization and geographic expansion. Earnings per share (EPS) came in at $0.08, missing estimates of $0.2449. Despite the EPS miss, the company's revenue growth was in line with expectations.
Publication Date: Dec -04
The company delivered growth across regions, with EMEA and LatAm up 5.3%, Asia Pacific up 5.1%, and North America up 0.4%. The company is on track to deliver its full-year guidance of around 3.5% organic revenue growth and high single-digit organic operating profit growth. Haleon expects to return to growth in North America in 2026, driven by innovation, net revenue management, and strengthened relationships with partners.
The innovation pipeline for 2026 is strong, with a focus on driving category growth through innovation-led premiumization. Notable performances came from Sensodyne Clinical, Otrivin Nasal Mist, and Centrum. In Oral Health, the Clinical range on Sensodyne continues to perform well, gaining or holding share in over 80% of brand market combinations.
Using the current valuation metrics, Haleon's P/E Ratio stands at 21.49, and its P/S Ratio is 2.92. The company's ROE is 9.4%, and ROIC is 6.24%. Analysts estimate next year's revenue growth at 4.8%, which is slightly higher than the company's medium-term guidance of 4% to 6% growth.
The company guides for minus 0.5% growth in the U.S. this year, with sell-out around minus 1% to minus 1.5%. The company expects an acceleration in Asia Pac, particularly in India and strong continued growth in China. Haleon is confident in its medium-term guidance and is working closely with retailers to ensure the right inventory levels.
The company reduced its SKU count by 19%, which is helping to improve productivity and shopability. Haleon is making efforts to improve service levels and reduce inventory. The company is also increasing investment in the 11/11 event, a key growth driver in Q4.
Cetera Investment Advisers Sells 13,326 Shares of Haleon PLC Sponsored ADR $HLN
Dec -02
First Eagle Overseas Equity ETF Q3 2025 Portfolio Update
Nov -26
Altibbi Enables Haleon's "Healthy Saudi Smile" Campaign, Turning Oral Health Awareness Into Action
Nov -24
Bank of New York Mellon Corp Has $23.37 Million Stake in Haleon PLC Sponsored ADR $HLN
Nov -16
D.A. Davidson & CO. Trims Position in Haleon PLC Sponsored ADR $HLN
Oct -31
Haleon not out of the woods yet, with analysts saying questions still remain
Oct -30
Haleon plc (HLN) Q3 2025 Sales Call Transcript
Oct -30
Haleon outlook held steady as organic growth improves in third quarter
Oct -30
Haleon plc's EMEA and Latam segments are expected to grow driven by increasing demand for consumer healthcare products, expansion in emerging markets, and a shift towards self-care and preventative health measures
None
Haleon plc’s Asia Pacific region is driven by growing demand for healthcare products, increasing disposable incomes, and a large population with unmet healthcare needs, particularly in China and India.
Haleon's pain relief products provide fast and effective relief from headaches, backaches, and other types of pain.
Haleon's vitamins and supplements support overall health and wellness, including immune system support and energy boosting.
Haleon's cold and flu products provide relief from symptoms such as congestion, cough, and fever.
Haleon's digestive health products support healthy digestion, relieve heartburn and indigestion, and promote regularity.
Haleon's skin health products provide relief from skin conditions such as acne, eczema, and psoriasis.
Haleon's allergy relief products provide relief from seasonal and perennial allergies.
Haleon's sleep aids promote healthy sleep patterns and provide relief from insomnia and restlessness.
Haleon plc's products are moderately susceptible to substitutes, as consumers have some alternatives for pain relief and wellness products.
Haleon plc's customers have limited bargaining power due to the company's strong brand portfolio and wide distribution network.
Haleon plc's suppliers have moderate bargaining power, as the company relies on a diverse supplier base for raw materials and manufacturing.
The threat of new entrants is low for Haleon plc, as the company has a strong brand presence and significant barriers to entry in the pharmaceutical industry.
The intensity of rivalry is high in the pharmaceutical industry, with many established players competing for market share.
| Value | |
|---|---|
| Debt Weight | 36.28% |
| Debt Cost | 5.44% |
| Equity Weight | 63.72% |
| Equity Cost | 5.44% |
| WACC | 5.44% |
| Leverage | 56.94% |
Value: 5.2
Growth: 5.9
Quality: 8.2
Yield: 8.1
Momentum: 8.0
Volatility: 9.0
1-Year Total Return ->
Value: 3.9
Growth: 2.2
Quality: 6.5
Yield: 6.9
Momentum: 7.5
Volatility: 7.3
1-Year Total Return ->
Value: 5.0
Growth: 6.0
Quality: 7.7
Yield: 1.2
Momentum: 6.0
Volatility: 7.3
1-Year Total Return ->
Value: 3.5
Growth: 6.0
Quality: 6.7
Yield: 3.1
Momentum: 2.0
Volatility: 9.0
1-Year Total Return ->
Value: 3.5
Growth: 8.8
Quality: 8.0
Yield: 5.0
Momentum: 0.0
Volatility: 1.3
1-Year Total Return ->
Value: 4.2
Growth: 4.9
Quality: 6.5
Yield: 3.1
Momentum: 1.0
Volatility: 6.7
1-Year Total Return ->